- Home
- JNJ vs ABBV Comparison
JNJ vs ABBV Comparison
Compare JNJ & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JNJ | ABBV |
|---|---|---|
| Founded | 1886 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.6B | 403.2B |
| IPO Year | 1944 | N/A |
Fundamental Metrics
Financial Performance| Metric | JNJ | ABBV |
|---|---|---|
| Price | $205.64 | $230.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 18 |
| Target Price | $198.00 | ★ $240.12 |
| AVG Volume (30 Days) | ★ 9.0M | 5.9M |
| Earning Date | 01-21-2026 | 10-31-2025 |
| Dividend Yield | 2.53% | ★ 3.01% |
| EPS Growth | ★ 71.26 | N/A |
| EPS | ★ 10.35 | 1.32 |
| Revenue | ★ $92,149,000,000.00 | $59,644,000,000.00 |
| Revenue This Year | $6.60 | $10.00 |
| Revenue Next Year | $5.28 | $9.17 |
| P/E Ratio | ★ $19.84 | $174.34 |
| Revenue Growth | 5.08 | ★ 7.40 |
| 52 Week Low | $140.68 | $164.39 |
| 52 Week High | $207.81 | $244.81 |
Technical Indicators
Market Signals| Indicator | JNJ | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 74.53 | 53.70 |
| Support Level | $203.10 | $223.11 |
| Resistance Level | $207.70 | $229.49 |
| Average True Range (ATR) | 2.90 | 5.78 |
| MACD | 0.27 | -0.47 |
| Stochastic Oscillator | 84.89 | 46.11 |
Price Performance
Historical ComparisonAbout JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.